Gyre Therapeutics (GYRE) Operating Leases (2019 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Operating Leases of $72000.0 for Q1 2026, down 90.77% year-over-year from $780000.0 in Q1 2025, and down 76.24% quarter-over-quarter from $303000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Operating Leases (2019 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Operating Leases for 8 consecutive years, with $72000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 90.77% year-over-year to $72000.0; the TTM figure through Mar 2026 stood at $72000.0 (down 90.77% YoY), while the FY2025 annual figure was $303000.0, down 65.76% from the prior year.
- Operating Leases eased to $72000.0 in Q1 2026 per GYRE's latest filing, from $303000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.3 million in Q2 2024 and bottomed at $72000.0 in Q1 2026.
- Historically, Operating Leases has averaged $567545.5 across 5 years, with a median of $539000.0 in 2025.
- Annual changes were most pronounced in 2025 — Operating Leases soared 345.71% — and 2026, when it sank 90.77%.
- Gyre Therapeutics' Operating Leases stood at $121000.0 in 2022, then jumped by 64.46% to $199000.0 in 2023, then soared by 344.72% to $885000.0 in 2024, then plunged by 65.76% to $303000.0 in 2025, then plunged by 76.24% to $72000.0 in 2026.
- Business Quant data shows GYRE's Operating Leases at $72000.0 in Q1 2026, $303000.0 in Q4 2025, and $539000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 539,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 885,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 199,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Dec 31, 2021 | 408,000.00 |
| Sep 30, 2021 | 550,000.00 |
| Jun 30, 2021 | 1.05 Mn |
| Mar 31, 2021 | 806,000.00 |
| Dec 31, 2020 | 981,000.00 |
| Sep 30, 2020 | 925,000.00 |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.19 Mn |